Journal: Molecular Biology Reports

Article Title: Feasibility of a quantitative polymerase chain reaction assay for diagnosing pneumococcal pneumonia using oropharyngeal swabs

doi: 10.1007/s11033-018-4558-0

Figure Lengend Snippet: Patient characteristics

Article Snippet: The calculated average concentration of S. pneumoniae (ATCC 49619) was used to assess a standard curve.

Techniques:

Journal:

Article Title: Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection Models

doi: 10.1128/AAC.46.6.1665-1670.2002

Figure Lengend Snippet: In vitro susceptibilities of the strains tested to gatifloxacin, penicillin, methicillin, and ciprofloxacin

Article Snippet: The magnitudes of the parameter needed to achieve a static effect were 1.3- to 2.2-fold lower in the nonneutropenic infection model. table ft1 table-wrap mode="anchored" t5 TABLE 3. caption a7 Organism MIC (μg/ml) 24-h AUC/MIC ratio required for: Static effect 1 log 10 kill 2 log 10 killing S. pneumoniae CDC 145 0.25 37.0 45.8 56.1 S. pneumoniae CDC 146 0.25 54.8 66.7 81.4 S. pneumoniae CDC 673 0.25 53.6 64.4 78.4 S. pneumoniae CDC 1020 0.50 57.6 81.1 114 S. pneumoniae ATCC 10813 0.25 72.4 107.7 160.0 S. pneumoniae ATCC 49619 0.25 40.0 45.2 50.9 S. pneumoniae CDC 1396 0.50 18.4 24.9 33.8 S. pneumoniae MNO-418 8.0 23.1 33.4 45.3 S. pneumoniae T6-2668 2.0 51.3 80.5 128 Mean ± SD 52.0 ± 20.3 61.1 ± 26.4 83.1 ± 42.6 S. aureus ATCC 25923 0.12 27.2 47.8 76.5 S. aureus ATCC 33591 0.12 45.6 74.2 113 S. aureus ATCC 29213 0.12 29.7 54.5 90.9 S. aureus ATCC 6538p 0.06 43.2 131 507 Mean ± SD 36.4 ± 9.3 76.9 ± 37.8 197 ± 207 E. coli ATCC 25922 0.015 54.1 86.5 133 K. pneumoniae ATCC 43816 (thigh model, neutropenic mice) 0.06 69.7 129 235 K. pneumoniae ATCC 43816 (thigh model, nonneutropenic mice) 0.06 32.2 62.2 165 a K. pneumoniae ATCC 43816 (lung model, neutropenic mice) 0.06 55.9 96.1 153 K. pneumoniae ATCC 43816 (lung model, nonneutropenic mice) 0.06 43.2 63.2 91 a E. cloacae L2249 0.12 16.4 32.8 64.8 E. cloacae L4567 0.12 27.3 57.4 132 P. aeruginosa ATCC 27853 2.0 23.6 31.2 41.0 Mean ± SD 41.2 ± 21.5 72.2 ± 38.6 126 ± 68.8 Open in a separate window a Datum not included in calculation of the mean.

Techniques: In Vitro

Journal:

Article Title: Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection Models

doi: 10.1128/AAC.46.6.1665-1670.2002

Figure Lengend Snippet: In vivo PAEs of gatifloxacin after administration of single doses of 8 and 32 mg/kg against S. pneumoniae ATCC 10813 (A) and S. aureus ATCC 6538p (B). Each symbol represents the mean ± standard deviation for two mice. The widths of the bars represent the duration of time that levels in serum exceeded the MIC for the infecting pathogen.

Article Snippet: The magnitudes of the parameter needed to achieve a static effect were 1.3- to 2.2-fold lower in the nonneutropenic infection model. table ft1 table-wrap mode="anchored" t5 TABLE 3. caption a7 Organism MIC (μg/ml) 24-h AUC/MIC ratio required for: Static effect 1 log 10 kill 2 log 10 killing S. pneumoniae CDC 145 0.25 37.0 45.8 56.1 S. pneumoniae CDC 146 0.25 54.8 66.7 81.4 S. pneumoniae CDC 673 0.25 53.6 64.4 78.4 S. pneumoniae CDC 1020 0.50 57.6 81.1 114 S. pneumoniae ATCC 10813 0.25 72.4 107.7 160.0 S. pneumoniae ATCC 49619 0.25 40.0 45.2 50.9 S. pneumoniae CDC 1396 0.50 18.4 24.9 33.8 S. pneumoniae MNO-418 8.0 23.1 33.4 45.3 S. pneumoniae T6-2668 2.0 51.3 80.5 128 Mean ± SD 52.0 ± 20.3 61.1 ± 26.4 83.1 ± 42.6 S. aureus ATCC 25923 0.12 27.2 47.8 76.5 S. aureus ATCC 33591 0.12 45.6 74.2 113 S. aureus ATCC 29213 0.12 29.7 54.5 90.9 S. aureus ATCC 6538p 0.06 43.2 131 507 Mean ± SD 36.4 ± 9.3 76.9 ± 37.8 197 ± 207 E. coli ATCC 25922 0.015 54.1 86.5 133 K. pneumoniae ATCC 43816 (thigh model, neutropenic mice) 0.06 69.7 129 235 K. pneumoniae ATCC 43816 (thigh model, nonneutropenic mice) 0.06 32.2 62.2 165 a K. pneumoniae ATCC 43816 (lung model, neutropenic mice) 0.06 55.9 96.1 153 K. pneumoniae ATCC 43816 (lung model, nonneutropenic mice) 0.06 43.2 63.2 91 a E. cloacae L2249 0.12 16.4 32.8 64.8 E. cloacae L4567 0.12 27.3 57.4 132 P. aeruginosa ATCC 27853 2.0 23.6 31.2 41.0 Mean ± SD 41.2 ± 21.5 72.2 ± 38.6 126 ± 68.8 Open in a separate window a Datum not included in calculation of the mean.

Techniques: In Vivo, Standard Deviation

Journal:

Article Title: Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection Models

doi: 10.1128/AAC.46.6.1665-1670.2002

Figure Lengend Snippet: Relationships of the gatifloxacin 24-h AUC/MIC (A), peak level/MIC (B), and T>MIC (C) for S. pneumoniae ATCC 10813 with the log10 numbers of CFU per thigh after 24 h of therapy. Each symbol represents the mean for two thighs per mouse. The horizontal dashed lines represent the organism burden at the start of therapy.

Article Snippet: The magnitudes of the parameter needed to achieve a static effect were 1.3- to 2.2-fold lower in the nonneutropenic infection model. table ft1 table-wrap mode="anchored" t5 TABLE 3. caption a7 Organism MIC (μg/ml) 24-h AUC/MIC ratio required for: Static effect 1 log 10 kill 2 log 10 killing S. pneumoniae CDC 145 0.25 37.0 45.8 56.1 S. pneumoniae CDC 146 0.25 54.8 66.7 81.4 S. pneumoniae CDC 673 0.25 53.6 64.4 78.4 S. pneumoniae CDC 1020 0.50 57.6 81.1 114 S. pneumoniae ATCC 10813 0.25 72.4 107.7 160.0 S. pneumoniae ATCC 49619 0.25 40.0 45.2 50.9 S. pneumoniae CDC 1396 0.50 18.4 24.9 33.8 S. pneumoniae MNO-418 8.0 23.1 33.4 45.3 S. pneumoniae T6-2668 2.0 51.3 80.5 128 Mean ± SD 52.0 ± 20.3 61.1 ± 26.4 83.1 ± 42.6 S. aureus ATCC 25923 0.12 27.2 47.8 76.5 S. aureus ATCC 33591 0.12 45.6 74.2 113 S. aureus ATCC 29213 0.12 29.7 54.5 90.9 S. aureus ATCC 6538p 0.06 43.2 131 507 Mean ± SD 36.4 ± 9.3 76.9 ± 37.8 197 ± 207 E. coli ATCC 25922 0.015 54.1 86.5 133 K. pneumoniae ATCC 43816 (thigh model, neutropenic mice) 0.06 69.7 129 235 K. pneumoniae ATCC 43816 (thigh model, nonneutropenic mice) 0.06 32.2 62.2 165 a K. pneumoniae ATCC 43816 (lung model, neutropenic mice) 0.06 55.9 96.1 153 K. pneumoniae ATCC 43816 (lung model, nonneutropenic mice) 0.06 43.2 63.2 91 a E. cloacae L2249 0.12 16.4 32.8 64.8 E. cloacae L4567 0.12 27.3 57.4 132 P. aeruginosa ATCC 27853 2.0 23.6 31.2 41.0 Mean ± SD 41.2 ± 21.5 72.2 ± 38.6 126 ± 68.8 Open in a separate window a Datum not included in calculation of the mean.

Techniques:

Journal:

Article Title: Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection Models

doi: 10.1128/AAC.46.6.1665-1670.2002

Figure Lengend Snippet: Relationship between gatifloxacin dosing interval and bacteriostatic efficacy

Article Snippet: The magnitudes of the parameter needed to achieve a static effect were 1.3- to 2.2-fold lower in the nonneutropenic infection model. table ft1 table-wrap mode="anchored" t5 TABLE 3. caption a7 Organism MIC (μg/ml) 24-h AUC/MIC ratio required for: Static effect 1 log 10 kill 2 log 10 killing S. pneumoniae CDC 145 0.25 37.0 45.8 56.1 S. pneumoniae CDC 146 0.25 54.8 66.7 81.4 S. pneumoniae CDC 673 0.25 53.6 64.4 78.4 S. pneumoniae CDC 1020 0.50 57.6 81.1 114 S. pneumoniae ATCC 10813 0.25 72.4 107.7 160.0 S. pneumoniae ATCC 49619 0.25 40.0 45.2 50.9 S. pneumoniae CDC 1396 0.50 18.4 24.9 33.8 S. pneumoniae MNO-418 8.0 23.1 33.4 45.3 S. pneumoniae T6-2668 2.0 51.3 80.5 128 Mean ± SD 52.0 ± 20.3 61.1 ± 26.4 83.1 ± 42.6 S. aureus ATCC 25923 0.12 27.2 47.8 76.5 S. aureus ATCC 33591 0.12 45.6 74.2 113 S. aureus ATCC 29213 0.12 29.7 54.5 90.9 S. aureus ATCC 6538p 0.06 43.2 131 507 Mean ± SD 36.4 ± 9.3 76.9 ± 37.8 197 ± 207 E. coli ATCC 25922 0.015 54.1 86.5 133 K. pneumoniae ATCC 43816 (thigh model, neutropenic mice) 0.06 69.7 129 235 K. pneumoniae ATCC 43816 (thigh model, nonneutropenic mice) 0.06 32.2 62.2 165 a K. pneumoniae ATCC 43816 (lung model, neutropenic mice) 0.06 55.9 96.1 153 K. pneumoniae ATCC 43816 (lung model, nonneutropenic mice) 0.06 43.2 63.2 91 a E. cloacae L2249 0.12 16.4 32.8 64.8 E. cloacae L4567 0.12 27.3 57.4 132 P. aeruginosa ATCC 27853 2.0 23.6 31.2 41.0 Mean ± SD 41.2 ± 21.5 72.2 ± 38.6 126 ± 68.8 Open in a separate window a Datum not included in calculation of the mean.

Techniques:

Journal:

Article Title: Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection Models

doi: 10.1128/AAC.46.6.1665-1670.2002

Figure Lengend Snippet: Relationship between gatifloxacin MIC and AUC/MIC necessary to achieve a static effect and 1 log 10 and 2 log 10 killing

Article Snippet: The magnitudes of the parameter needed to achieve a static effect were 1.3- to 2.2-fold lower in the nonneutropenic infection model. table ft1 table-wrap mode="anchored" t5 TABLE 3. caption a7 Organism MIC (μg/ml) 24-h AUC/MIC ratio required for: Static effect 1 log 10 kill 2 log 10 killing S. pneumoniae CDC 145 0.25 37.0 45.8 56.1 S. pneumoniae CDC 146 0.25 54.8 66.7 81.4 S. pneumoniae CDC 673 0.25 53.6 64.4 78.4 S. pneumoniae CDC 1020 0.50 57.6 81.1 114 S. pneumoniae ATCC 10813 0.25 72.4 107.7 160.0 S. pneumoniae ATCC 49619 0.25 40.0 45.2 50.9 S. pneumoniae CDC 1396 0.50 18.4 24.9 33.8 S. pneumoniae MNO-418 8.0 23.1 33.4 45.3 S. pneumoniae T6-2668 2.0 51.3 80.5 128 Mean ± SD 52.0 ± 20.3 61.1 ± 26.4 83.1 ± 42.6 S. aureus ATCC 25923 0.12 27.2 47.8 76.5 S. aureus ATCC 33591 0.12 45.6 74.2 113 S. aureus ATCC 29213 0.12 29.7 54.5 90.9 S. aureus ATCC 6538p 0.06 43.2 131 507 Mean ± SD 36.4 ± 9.3 76.9 ± 37.8 197 ± 207 E. coli ATCC 25922 0.015 54.1 86.5 133 K. pneumoniae ATCC 43816 (thigh model, neutropenic mice) 0.06 69.7 129 235 K. pneumoniae ATCC 43816 (thigh model, nonneutropenic mice) 0.06 32.2 62.2 165 a K. pneumoniae ATCC 43816 (lung model, neutropenic mice) 0.06 55.9 96.1 153 K. pneumoniae ATCC 43816 (lung model, nonneutropenic mice) 0.06 43.2 63.2 91 a E. cloacae L2249 0.12 16.4 32.8 64.8 E. cloacae L4567 0.12 27.3 57.4 132 P. aeruginosa ATCC 27853 2.0 23.6 31.2 41.0 Mean ± SD 41.2 ± 21.5 72.2 ± 38.6 126 ± 68.8 Open in a separate window a Datum not included in calculation of the mean.

Techniques:

Journal: Current Research in Biotechnology

Article Title: Biotechnological and pharmacological assessment of pyocyanin from marine Pseudomonas otitidis EGY-NIOF-A1 as an antimicrobial agent against clinical pathogens

doi: 10.1016/j.crbiot.2023.100156

Figure Lengend Snippet: Fig. 5. The antimicrobial effects of marine-derived pyocyanin at different concentrations against the sensitive microorganisms. Figure represents the CFU quanti fication (A) against S. pneumoniae (pyocyanin 0.844 µg/mL), (B) against S. aureus (pyocyanin 0.844 µg/mL), and (C) against E. faecalis (pyocyanin 2.112 µg/mL). Data were expressed as mean ± SD (n = 3) and statistically analyzed using Mann-Whitney U test. The significance was considered when * p ≤0.05.

Article Snippet: The antimicrobial effects of the purified marine compound were tested against eight microorganisms including Escherichia coli (E. coli; ATCC 25922), Klebsiella pneumoniae (K. pneumoniae; ATCC 700603), Streptococcus pneumoniae (S. pneumoniae; ATCC 49619), Salmonella typhimurium (S. typhimurium; ATCC 14028), Staphylococcus aureus (S. aureus; ATCC 29213), Methicillin-resistant Staphylococcus aureus (MRSA; ATCC 43300), Enterococcus faecalis (E. faecalis; ATCC 29212), Candida albicans (C. albicans; ATCC 90028).

Techniques: Derivative Assay, MANN-WHITNEY

Journal: Current Research in Biotechnology

Article Title: Biotechnological and pharmacological assessment of pyocyanin from marine Pseudomonas otitidis EGY-NIOF-A1 as an antimicrobial agent against clinical pathogens

doi: 10.1016/j.crbiot.2023.100156

Figure Lengend Snippet: Fig. 4. Agar well-diffusion analysis of the antimicrobial effects of marine-derived pyocyanin at different concentrations including 4.4, 3.52, 2.112, 0.844, and 0.169 µg/mL against eight clinical pathogens as compared to negative and positive controls. (A) E. coli, (B) K. pneumoniae, (C) S. pneumoniae, (D) S. typhimurium, (E) S. aureus, (F) MRSA, (G) E. faecalis, and (H) C. albicans. Data were expressed as mean ± SD (n = 3) and statistically analyzed using Kruskal-Walli’s test followed by Dunn’s Multiple Comparison Test. The significance was considered when * p ≤0.05 and ** p ≤0.01.

Article Snippet: The antimicrobial effects of the purified marine compound were tested against eight microorganisms including Escherichia coli (E. coli; ATCC 25922), Klebsiella pneumoniae (K. pneumoniae; ATCC 700603), Streptococcus pneumoniae (S. pneumoniae; ATCC 49619), Salmonella typhimurium (S. typhimurium; ATCC 14028), Staphylococcus aureus (S. aureus; ATCC 29213), Methicillin-resistant Staphylococcus aureus (MRSA; ATCC 43300), Enterococcus faecalis (E. faecalis; ATCC 29212), Candida albicans (C. albicans; ATCC 90028).

Techniques: Diffusion-based Assay, Derivative Assay, Comparison

Journal: Journal of Traditional and Complementary Medicine

Article Title: Antibacterial oral sprays from kaffir lime ( Citrus hystrix DC.) fruit peel oil and leaf oil and their activities against respiratory tract pathogens

doi: 10.1016/j.jtcme.2019.09.003

Figure Lengend Snippet: Antibacterial activity of three Kaffir lime fruit peel oil oral sprays and three Kaffir lime leaf oil oral sprays against one Group A streptococcal clinical isolate and 3 standard strains of respiratory tract pathogenic bacteria, using broth microdilution method.

Article Snippet: All oral sprays exhibited antibacterial activity against a Group A streptococcal clinical isolate and three respiratory pathogens ( S. aureus ATCC 29213, S. pneumoniae ATCC 49619, and H. influenza e ATCC 49247), with the strongest activity against H. influenza e ATCC 49247.

Techniques: Activity Assay, Bacteria

Journal: Journal of Clinical Microbiology

Article Title: Performance assessment of the Bruker Biotyper MALDI-TOF MS for the identification of difficult-to-identify viridans group streptococci

doi: 10.1128/jcm.01143-23

Figure Lengend Snippet: Identification results of the three Bruker Biotyper systems for the reference strains

Article Snippet: TABLE 1 Group Strain 16S rDNA (%) a MALDI TOF MS Biotyper 3.1 (DB_5627) Biotyper 3.1 (DB_6903) Biotyper 4.1 (DB_10833) ID b Group ID b Group ID b Group Mitis S. mitis ATCC 49456 100 Spn Mitis Smi Mitis Smi Mitis Mitis S. oralis ATCC 35037 100 Spn Mitis Sor Mitis Sor Mitis Mitis S. pseudopneumoniae ATCC BAA-960 100 Spn Mitis Sps Mitis Sps Mitis Mitis S. pneumoniae ATCC 49619 100 ND c ND c Spn Mitis Spn Mitis Mitis S. pneumoniae ATCC 6301 100 ND c ND c Spn Mitis Spn Mitis Mitis S. pneumoniae ATCC 6305 100 ND c ND c Spn Mitis Spn Mitis Mitis S. pneumoniae ATCC BAA-255 100 ND c ND c Spn Mitis Spn Mitis Mitis S. pneumoniae ATCC 33400 100 ND c ND c Spn Mitis Spn Mitis Bovis S. gallolyticus ATCC 43144 100 ND c ND c Sga Bovis Sga Bovis Bovis S. equinus ATCC 33317 100 ND c ND c Slu Bovis Slu Bovis Bovis S. infantarius ATCC BAA-102 100 ND c ND c Seq Bovis Sinf Bovis Bovis S. lutetiensis ATCC BAA-103 99.93 ND c ND c Slu Bovis Slu Bovis Anginosus S. anginosus ATCC 9895 100 San Anginosus San Anginosus San Anginosus Anginosus S. constellatus ATCC 27513 100 Sco Anginosus Sco Anginosus Sco Anginosus Anginosus S. intermedius ATCC 27335 100 Sint Anginosus Sint Anginosus Sint Anginosus Sanguinis S. sanguinis ATCC 10556 100 Ssan Sanguinis Ssan Sanguinis Ssan Sanguinis Sanguinis S. parasanguinis ATCC 15909 99.86 Spa Sanguinis Spa Sanguinis Spa Sanguinis Sanguinis S. gordonii ATCC 35105 100 Sgo Sanguinis Sgo Sanguinis Sgo Sanguinis Salivarius S. salivarius ATCC 7073 100 Ssal Salivarius Ssal Salivarius Ssal Salivarius Mutans S. mutans ATCC GS-5 100 Smu Mutans Smu Mutans Smu Mutans Open in a separate window a Percent homology to 16S rDNA sequences in the NCBI database. b The text in bold indicates discrepant results.

Techniques:

Journal: Journal of Clinical Microbiology

Article Title: Performance assessment of the Bruker Biotyper MALDI-TOF MS for the identification of difficult-to-identify viridans group streptococci

doi: 10.1128/jcm.01143-23

Figure Lengend Snippet: Accuracy ratios of VGS species identification among clinical isolates using three Bruker Biotyper systems

Article Snippet: TABLE 1 Group Strain 16S rDNA (%) a MALDI TOF MS Biotyper 3.1 (DB_5627) Biotyper 3.1 (DB_6903) Biotyper 4.1 (DB_10833) ID b Group ID b Group ID b Group Mitis S. mitis ATCC 49456 100 Spn Mitis Smi Mitis Smi Mitis Mitis S. oralis ATCC 35037 100 Spn Mitis Sor Mitis Sor Mitis Mitis S. pseudopneumoniae ATCC BAA-960 100 Spn Mitis Sps Mitis Sps Mitis Mitis S. pneumoniae ATCC 49619 100 ND c ND c Spn Mitis Spn Mitis Mitis S. pneumoniae ATCC 6301 100 ND c ND c Spn Mitis Spn Mitis Mitis S. pneumoniae ATCC 6305 100 ND c ND c Spn Mitis Spn Mitis Mitis S. pneumoniae ATCC BAA-255 100 ND c ND c Spn Mitis Spn Mitis Mitis S. pneumoniae ATCC 33400 100 ND c ND c Spn Mitis Spn Mitis Bovis S. gallolyticus ATCC 43144 100 ND c ND c Sga Bovis Sga Bovis Bovis S. equinus ATCC 33317 100 ND c ND c Slu Bovis Slu Bovis Bovis S. infantarius ATCC BAA-102 100 ND c ND c Seq Bovis Sinf Bovis Bovis S. lutetiensis ATCC BAA-103 99.93 ND c ND c Slu Bovis Slu Bovis Anginosus S. anginosus ATCC 9895 100 San Anginosus San Anginosus San Anginosus Anginosus S. constellatus ATCC 27513 100 Sco Anginosus Sco Anginosus Sco Anginosus Anginosus S. intermedius ATCC 27335 100 Sint Anginosus Sint Anginosus Sint Anginosus Sanguinis S. sanguinis ATCC 10556 100 Ssan Sanguinis Ssan Sanguinis Ssan Sanguinis Sanguinis S. parasanguinis ATCC 15909 99.86 Spa Sanguinis Spa Sanguinis Spa Sanguinis Sanguinis S. gordonii ATCC 35105 100 Sgo Sanguinis Sgo Sanguinis Sgo Sanguinis Salivarius S. salivarius ATCC 7073 100 Ssal Salivarius Ssal Salivarius Ssal Salivarius Mutans S. mutans ATCC GS-5 100 Smu Mutans Smu Mutans Smu Mutans Open in a separate window a Percent homology to 16S rDNA sequences in the NCBI database. b The text in bold indicates discrepant results.

Techniques: